FDA Extends PDUFA Date for Eton Pharmaceuticals’ ET-400
FDA extends PDUFA goal date for Eton’s ET-400 NDA to May 28, 2025, requiring additional review time.
.webp&w=1920&q=75&dpl=dpl_DvHKTkTrxtw9jHK6MpkEndZCmmr3)
Eton Pharmaceuticals has announced that the U.S. FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for its New Drug Application (NDA) for ET-400, a treatment for pediatric rare diseases. Originally set for February 28, 2025, the new decision date is now May 28, 2025, allowing the FDA additional time to review supplemental information submitted in December.
Despite the extension, Eton remains optimistic about approval and its commercial launch this year. CEO Sean Brynjelsen reassured stakeholders that the company has fully addressed the FDA’s inquiries and expects no major impact on its 2025 revenue forecasts. The decision marks a key step in ensuring regulatory clarity and timely patient access to this critical therapy.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion